Selenite induces posttranscriptional blockade of HLA-E expression and sensitizes tumor cells to CD94/NKG2A-positive NK cells

Journal of Immunology

Volumn 187, Issue 7, 2011, Pages 3546-3554

  Enqvist, Monika ^a   Nilsonne, Gustav ^a   Hammarfjord, Oscar ^a   Wallin, Robert P A ^a   Björkström, Niklas K ^a   Björnstedt, Mikael ^a   Hjerpe, Anders ^a   Ljunggren, Hans Gustaf ^a   Dobra, Katalin ^a   Malmberg, Karl Johan ^a   Carlsten, Mattias ^a,b,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD94 ANTIGEN; HLA ANTIGEN CLASS 1; HLA E ANTIGEN; MESSENGER RNA; NATURAL KILLER CELL RECEPTOR NKG2A; SELENITE; SELENOMETHIONINE; THIOL;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL KILLING; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG SENSITIZATION; HUMAN; HUMAN CELL; NATURAL KILLER CELL; OXIDATIVE STRESS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SENSITIZATION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SEPARATION; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY D; OXIDATIVE STRESS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SODIUM SELENITE;

EID: 80053502639     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1100610     Document Type: Article

References (69)

1. Lanier, L. L. 2005. NK cell recognition. Annu. Rev. Immunol. 23: 225-274. (Pubitemid 40563170)
2. Fauriat, C., S. Andersson, A. T. Björklund, M. Carlsten, M. Schaffer, N. K. Björkström, B. C. Baumann, J. Michaëlsson, H. G. Ljunggren, and K. J. Malmberg. 2008. Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype. J. Immunol. 181: 6010-6019.
3. Yawata, M., N. Yawata, M. Draghi, F. Partheniou, A. M. Little, and P. Parham. 2008. MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood 112: 2369-2380.
4. Raulet, D. H., and R. E. Vance. 2006. Self-tolerance of natural killer cells. Nat. Rev. Immunol. 6: 520-531. (Pubitemid 43980524)
5. Cooley, S., F. Xiao, M. Pitt, M. Gleason, V. McCullar, T. L. Bergemann, K. L. McQueen, L. A. Guethlein, P. Parham, and J. S. Miller. 2007. A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood 110: 578-586. (Pubitemid 47105396)
6. Anfossi, N., P. André, S. Guia, C. S. Falk, S. Roetynck, C. A. Stewart, V. Breso, C. Frassati, D. Reviron, D. Middleton, et al. 2006. Human NK cell education by inhibitory receptors for MHC class I. Immunity 25: 331-342. (Pubitemid 44224147)
7. Uhrberg, M., N. M. Valiante, B. P. Shum, H. G. Shilling, K. Lienert-Weidenbach, B. Corliss, D. Tyan, L. L. Lanier, and P. Parham. 1997. Human diversity in killer cell inhibitory receptor genes. Immunity 7: 753-763. (Pubitemid 28064889)
8. Ljunggren, H. G., and K. Kärre. 1990. In search of the "missing self": MHC molecules and NK cell recognition. Immunol. Today 11: 237-244. (Pubitemid 20198988)
9. Borrego, F., M. Ulbrecht, E. H. Weiss, J. E. Coligan, and A. G. Brooks. 1998. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J. Exp. Med. 187: 813-818. (Pubitemid 28115198)
10. Braud, V. M., D. S. Allan, C. A. O'Callaghan, K. Söderström, A. D'Andrea, G. S. Ogg, S. Lazetic, N. T. Young, J. I. Bell, J. H. Phillips, et al. 1998. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391: 795-799. (Pubitemid 28099678)
11. Lee, N., M. Llano, M. Carretero, A. Ishitani, F. Navarro, M. López-Botet, and D. E. Geraghty. 1998. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl. Acad. Sci. USA 95: 5199-5204. (Pubitemid 28208575)
12. Lanier, L. L., B. Corliss, J. Wu, and J. H. Phillips. 1998. Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity 8: 693-701. (Pubitemid 28294516)
13. Le Dréan, E., F. Vély, L. Olcese, A. Cambiaggi, S. Guia, G. Krystal, N. Gervois, A. Moretta, F. Jotereau, and E. Vivier. 1998. Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases. Eur. J. Immunol. 28: 264-276. (Pubitemid 28048297)
14. Freud, A. G., and M. A. Caligiuri. 2006. Human natural killer cell development. Immunol. Rev. 214: 56-72. (Pubitemid 44707902)
15. Gonzalez, V. D., N. K. Björkström, K. J. Malmberg, M. Moll, C. Kuylenstierna, J. Michaëlsson, H. G. Ljunggren, and J. K. Sandberg. 2008. Application of ninecolor flow cytometry for detailed studies of the phenotypic complexity and functional heterogeneity of human lymphocyte subsets. J. Immunol. Methods 330: 64-74.
16. Sáez-Borderías, A., N. Romo, G. Magri, M. Gumá, A. Angulo, and M. López- Botet. 2009. IL-12-dependent inducible expression of the CD94/NKG2A inhibitory receptor regulates CD94/NKG2C+ NK cell function. J. Immunol. 182: 829-836.
17. Andersson, S., C. Fauriat, J. A. Malmberg, H. G. Ljunggren, and K. J. Malmberg. 2009. KIR acquisition probabilities are independent of self-HLA class I ligands and increase with cellular KIR expression. Blood 114: 95-104.
18. Shilling, H. G., N. Young, L. A. Guethlein, N. W. Cheng, C. M. Gardiner, D. Tyan, and P. Parham. 2002. Genetic control of human NK cell repertoire. J. Immunol. 169: 239-247. (Pubitemid 34686141)
19. Valiante, N. M., M. Uhrberg, H. G. Shilling, K. Lienert-Weidenbach, K. L. Arnett, A. D'Andrea, J. H. Phillips, L. L. Lanier, and P. Parham. 1997. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7: 739-751. (Pubitemid 28064888)
20. Marín, R., F. Ruiz-Cabello, S. Pedrinaci, R. Méndez, P. Jiménez, D. E. Geraghty, and F. Garrido. 2003. Analysis of HLA-E expression in human tumors. Immunogenetics 54: 767-775. (Pubitemid 36384471)
21. Malmberg, K. J., V. Levitsky, H. Norell, C. T. De Matos, M. Carlsten, K. Schedvins, H. Rabbani, A. Moretta, K. Söderström, J. Levitskaya, and R. Kiessling. 2002. IFN-g protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J. Clin. Invest. 110: 1515-1523. (Pubitemid 35396922)
22. Wischhusen, J., M. A. Friese, M. Mittelbronn, R. Meyermann, and M. Weller. 2005. HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. J. Neuropathol. Exp. Neurol. 64: 523-528. (Pubitemid 40781155)
23. Bianchini, M., E. Levy, C. Zucchini, V. Pinski, C. Macagno, P. De Sanctis, L. Valvassori, P. Carinci, and J. Mordoh. 2006. Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa. Int. J. Oncol. 29: 83-94.
24. Nguyen, S., V. Beziat, N. Dhedin, M. Kuentz, J. P. Vernant, P. Debre, and V. Vieillard. 2009. HLA-E upregulation on IFN-g-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT. Bone Marrow Transplant. 43: 693-699.
25. Derré, L., M. Corvaisier, B. Charreau, A. Moreau, E. Godefroy, A. Moreau- Aubry, F. Jotereau, and N. Gervois. 2006. Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J. Immunol. 177: 3100-3107. (Pubitemid 44277827)
26. Selenius, M., A. K. Rundlöf, E. Olm, A. P. Fernandes, and M. Björnstedt. 2010. Selenium and the selenoprotein thioredoxin reductase in the prevention, treatment and diagnostics of cancer. Antioxid. Redox Signal. 12: 867-880.
27. Arnér, E. S. 2009. Focus on mammalian thioredoxin reductases: important selenoproteins with versatile functions. Biochim. Biophys. Acta 1790: 495-526.
28. Lu, J., and A. Holmgren. 2009. Selenoproteins. J. Biol. Chem. 284: 723-727.
29. Nelson, M. A., B. W. Porterfield, E. T. Jacobs, and L. C. Clark. 1999. Selenium and prostate cancer prevention. Semin. Urol. Oncol. 17: 91-96. (Pubitemid 29203454)
30. Clark, L. C., G. F. Combs, Jr., B. W. Turnbull, E. H. Slate, D. K. Chalker, J. Chow, L. S. Davis, R. A. Glover, G. F. Graham, E. G. Gross, et al Nutritional Prevention of Cancer Study Group. 1996. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA 276: 1957-1963. (Pubitemid 26427723)
31. Rayman, M. P. 2000. The importance of selenium to human health. Lancet 356: 233-241. (Pubitemid 30446984)
32. Yu, S. Y., Y. J. Zhu, and W. G. Li. 1997. Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biol. Trace Elem. Res. 56: 117-124. (Pubitemid 27198254)
33. Björkhem-Bergman, L., K. Jönsson, L. C. Eriksson, J. M. Olsson, S. Lehmann, C. Paul, and M. Björnstedt. 2002. Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity: effects on thioredoxin reductase and glutathione reductase. Biochem. Pharmacol. 63: 1875-1884. (Pubitemid 34603452)
34. Jiang, C., H. Hu, B. Malewicz, Z. Wang, and J. Lü. 2004. Selenite-induced p53 Ser-15 phosphorylation and caspase-mediated apoptosis in LNCaP human prostate cancer cells. Mol. Cancer Ther. 3: 877-884. (Pubitemid 39193770)
35. Nilsonne, G., X. Sun, C. Nyström, A. K. Rundlöf, A. Potamitou Fernandes, M. Björnstedt, and K. Dobra. 2006. Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress. Free Radic. Biol. Med. 41: 874-885. (Pubitemid 44262481)
36. Selenius, M., A. P. Fernandes, O. Brodin, M. Björnstedt, and A. K. Rundlöf. 2008. Treatment of lung cancer cells with cytotoxic levels of sodium selenite: effects on the thioredoxin system. Biochem. Pharmacol. 75: 2092-2099.
37. Guan, L., B. Han, J. Li, Z. Li, F. Huang, Y. Yang, and C. Xu. 2009. Exposure of human leukemia NB4 cells to increasing concentrations of selenite switches the signaling from pro-survival to pro-apoptosis. Ann. Hematol. 88: 733-742.
38. Olm, E., K. Jönsson-Videsäter, I. Ribera-Cortada, A. P. Fernandes, L. C. Eriksson, S. Lehmann, A. K. Rundlöf, C. Paul, and M. Björnstedt. 2009. Selenite is a potent cytotoxic agent for human primary AML cells. Cancer Lett. 282: 116-123.
39. Bandura, L., J. Drukala, A. Wolnicka-Glubisz, M. Bjornstedt, and W. Korohoda. 2005. Differential effects of selenite and selenate on human melanocytes, keratinocytes, and melanoma cells. Biochem. Cell Biol. 83: 196-211. (Pubitemid 41113546)
40. Husbeck, B., L. Nonn, D. M. Peehl, and S. J. Knox. 2006. Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells. Prostate 66: 218-225. (Pubitemid 43191243)
41. Kandaş, N. O., C. Randolph, and M. C. Bosland. 2009. Differential effects of selenium on benign and malignant prostate epithelial cells: stimulation of LNCaP cell growth by noncytotoxic, low selenite concentrations. Nutr. Cancer 61: 251-264.
42. Jönsson-Videsäter, K., L. Björkhem-Bergman, A. Hossain, A. Söderberg, L. C. Eriksson, C. Paul, A. Rosén, and M. Björnstedt. 2004. Selenite-induced apoptosis in doxorubicin-resistant cells and effects on the thioredoxin system. Biochem. Pharmacol. 67: 513-522. (Pubitemid 38232891)
43. Wallig, M. A., M. J. Kuchan, and J. A. Milner. 1993. Differential effects of cyanohydroxybutene and selenium on normal and neoplastic canine mammary cells in vitro. Toxicol. Lett. 69: 97-105.
44. Ljunggren, H. G., and K. J. Malmberg. 2007. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7: 329-339.
45. Zitvogel, L., A. Tesniere, L. Apetoh, F. Ghiringhelli, and G. Kroemer. 2008. Immunological aspects of anticancer chemotherapy (in French). Bull. Acad. Natl. Med. 192: 1469-1487; discussion 1487-1469.
46. Papp, L. V., J. Lu, A. Holmgren, and K. K. Khanna. 2007. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid. Redox Signal. 9: 775-806. (Pubitemid 46919583)
47. Klominek, J., K. H. Robért, A. Hjerpe, B. Wickström, and G. Gahrton. 1989. Serum-dependent growth patterns of two, newly established human mesothelioma cell lines. Cancer Res. 49: 6118-6122. (Pubitemid 19274178)
48. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.
49. Bookout, A. L., C. L. Cummins, D. J. Mangelsdorf, J. M. Pesola, and M. F. Kramer. 2006. High-throughput real-time quantitative reverse transcription PCR. Curr. Protoc. Mol. Biol. Chapter 15: Unit 15.18.
50. Rundlof, A. K., A. P. Fernandes, M. Selenius, M. Babic, M. Shariatgorji, G. Nilsonne, L. L. Ilag, K. Dobra, and M. Bjornstedt. 2007. Quantification of alternative mRNA species and identification of thioredoxin reductase 1 isoforms in human tumor cells. Differentiation 75: 123-132.
51. Sun, X., L. Wei, J. Lidén, G. Hui, K. Dahlman-Wright, A. Hjerpe, and K. Dobra. 2005. Molecular characterization of tumour heterogeneity and malignant mesothelioma cell differentiation by gene profiling. J. Pathol. 207: 91-101. (Pubitemid 41200718)
52. Alter, G., J. M. Malenfant, and M. Altfeld. 2004. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294: 15-22. (Pubitemid 39626587)
53. Carlsten, M., K. J. Malmberg, and H. G. Ljunggren. 2009. Natural killer cellmediated lysis of freshly isolated human tumor cells. Int. J. Cancer 124: 757-762.
54. Eagle, R. A., and J. Trowsdale. 2007. Promiscuity and the single receptor: NKG2D. Nat. Rev. Immunol. 7: 737-744. (Pubitemid 47327391)
55. Brodin, P., K. Kärre, and P. Höglund. 2009. NK cell education: not an on-off switch but a tunable rheostat. Trends Immunol. 30: 143-149.
56. Braud, V., E. Y. Jones, and A. McMichael. 1997. The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur. J. Immunol. 27: 1164-1169. (Pubitemid 27197219)
57. Kim, I., W. Xu, and J. C. Reed. 2008. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat. Rev. Drug Discov. 7: 1013-1030.
58. Björkhem, L., H. Teclebrhan, E. Kesen, J. M. Olsson, L. C. Eriksson, and M. Björnstedt. 2001. Increased levels of cytosolic thioredoxin reductase activity and mRNA in rat liver nodules. J. Hepatol. 35: 259-264. (Pubitemid 32803482)
59. Spyrou, G., M. Björnstedt, S. Skog, and A. Holmgren. 1996. Selenite and selenate inhibit human lymphocyte growth via different mechanisms. Cancer Res. 56: 4407-4412. (Pubitemid 26330448)
60. - cystine transporter explains the cancer-specific cytotoxicity of selenite. Proc. Natl. Acad. Sci. USA 106: 11400-11405.
61. Forceville, X. 2007. Effects of high doses of selenium, as sodium selenite, in septic shock patients a placebo-controlled, randomized, double-blind, multicenter phase II study: selenium and sepsis. J. Trace Elem. Med. Biol. 21 (Suppl. 1): 62-65. (Pubitemid 350138412)
62. Manzanares, W., A. Biestro, F. Galusso, M. H. Torre, N. Manay, G. Facchin, and G. Hardy. 2010. High-dose selenium for critically ill patients with systemic inflammation: pharmacokinetics and pharmacodynamics of selenious acid: a pilot study. Nutrition 26: 634-640.
63. Berg, M., A. Lundqvist, P. McCoy, Jr., L. Samsel, Y. Fan, A. Tawab, and R. Childs. 2009. Clinical-grade ex vivo-expanded human natural killer cells upregulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 11: 341-355.
64. Draghi, M., N. Yawata, M. Gleimer, M. Yawata, N. M. Valiante, and P. Parham. 2005. Single-cell analysis of the human NK cell response to missing self and its inhibition by HLA class I. Blood 105: 2028-2035. (Pubitemid 40731788)
65. Carlsten, M., B. C. Baumann, M. Simonsson, M. Jädersten, A. M. Forsblom, C. Hammarstedt, Y. T. Bryceson, H. G. Ljunggren, E. Hellström-Lindberg, and K. J. Malmberg. 2010. Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome. Leukemia 24: 1607-1616.
66. Carlsten, M., N. K. Björkström, H. Norell, Y. Bryceson, T. Van Hall, B. C. Baumann, M. Hanson, K. Schedvins, R. Kiessling, H. G. Ljunggren, and K. J. Malmberg. 2007. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 67: 1317-1325.
67. Castriconi, R., A. Dondero, M. V. Corrias, E. Lanino, D. Pende, L. Moretta, C. Bottino, and A. Moretta. 2004. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1- poliovirus receptor interaction. Cancer Res. 64: 9180-9184. (Pubitemid 39665534)
68. Lakshmikanth, T., S. Burke, T. H. Ali, S. Kimpfler, F. Ursini, L. Ruggeri, M. Capanni, V. Umansky, A. Paschen, A. Sucker, et al. 2009. NCRs and DNAM- 1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J. Clin. Invest. 119: 1251-1263.
69. Pende, D., G. M. Spaggiari, S. Marcenaro, S. Martini, P. Rivera, A. Capobianco, M. Falco, E. Lanino, I. Pierri, R. Zambello, et al. 2005. Analysis of the receptorligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 105: 2066-2073. (Pubitemid 40731793)